DiaMedica Therapeutics (NASDAQ:DMAC) Given Buy Rating at HC Wainwright

DiaMedica Therapeutics (NASDAQ:DMAC)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued on Friday,Benzinga reports. They presently have a $7.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 69.90% from the stock’s current price.

Separately, Oppenheimer reiterated an “outperform” rating and issued a $6.00 price target on shares of DiaMedica Therapeutics in a research note on Friday, August 16th.

DiaMedica Therapeutics Stock Down 3.3 %

DMAC opened at $4.12 on Friday. The stock has a market capitalization of $176.13 million, a price-to-earnings ratio of -7.36 and a beta of 1.46. DiaMedica Therapeutics has a twelve month low of $2.14 and a twelve month high of $4.95. The company has a 50-day simple moving average of $4.30 and a 200 day simple moving average of $3.56.

Institutional Trading of DiaMedica Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in shares of DiaMedica Therapeutics by 26.3% during the first quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company’s stock worth $2,807,000 after buying an additional 211,351 shares in the last quarter. Magnolia Capital Advisors LLC bought a new position in DiaMedica Therapeutics in the second quarter valued at about $87,000. Blue Trust Inc. acquired a new stake in shares of DiaMedica Therapeutics during the third quarter valued at about $185,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of DiaMedica Therapeutics during the third quarter worth about $40,000. Institutional investors and hedge funds own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.